RotaTeq™ experimental formulation + RotaTeq™ existing formulation

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Rotavirus Gastroenteritis

Conditions

Rotavirus Gastroenteritis

Trial Timeline

Apr 29, 2013 → Mar 25, 2014

NCT ID

NCT01600092

About RotaTeq™ experimental formulation + RotaTeq™ existing formulation

RotaTeq™ experimental formulation + RotaTeq™ existing formulation is a phase 3 stage product being developed by Merck for Rotavirus Gastroenteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01600092. Target conditions include Rotavirus Gastroenteritis.

What happened to similar drugs?

1 of 12 similar drugs in Rotavirus Gastroenteritis were approved

Approved (1) Terminated (1) Active (10)

✅RotaTeq™ (V260) + DTP-IPVMerckApproved

❌Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)MerckPhase 3

🔄RotaTeq™, rotavirus vaccine, live, oral, pentavalent + Comparator: Placebo matching RotaTeq™MerckPhase 3

🔄Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Oral Poliovirus Vaccine (OPV) + Comparator: Oral Poliovirus Vaccine (OPV) (staggered)MerckPhase 3

🔄RotaTeq (V260) + IPVMerckPhase 3

🔄Rotateq™ + Comparator: PlaceboMerckPhase 3

🔄Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: PlaceboMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01600092	Phase 3	Completed	Apr 29, 2013	Mar 25, 2014	Rotavirus Gastroenteritis

Competing Products

14 competing products in Rotavirus Gastroenteritis

See all competitors

Product	Company	Stage	Hype Score
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)	Merck	Phase 3	32
RotaTeq™, rotavirus vaccine, live, oral, pentavalent + Comparator: Placebo matching RotaTeq™	Merck	Phase 3	40
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Oral Poliovirus Vaccine (OPV) + Comparator: Oral Poliovirus Vaccine (OPV) (staggered)	Merck	Phase 3	40
RotaTeq (V260) + IPV	Merck	Phase 3	40
Rotateq™ + Comparator: Placebo	Merck	Phase 3	40
RotaTeq™ (V260) + DTP-IPV	Merck	Approved	43
Comparator: RotaTeq + Comparator: Placebo + Comparator: RotaTeq + Placebo	Merck	Phase 1	21
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo	Merck	Phase 3	40
V260 + Placebo to V260 + OPV + DTaP	Merck	Phase 3	40
rotavirus vaccine, live, oral, pentavalent + Placebo	Merck	Phase 3	40
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo + Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo	Merck	Phase 1	29
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: placebo + Comparator: Infanrix(tm) Hexa	Merck	Phase 3	40
Rotarix + RotaTeq	Merck	Phase 3	40
Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™) + Comparator: Comparator: Placebo (unspecified)	Merck	Phase 3	40